Select a State

Global health R&D delivers for North Carolina

US government investment in global health R&D has delivered

$410.0 million
to North Carolina research institutions
5,900+ new jobs
for North Carolina

Neglected diseases in North Carolina

Chikungunya cases
74
Dengue cases
62
HIV diagnoses
12,904
Malaria cases
272
Tuberculosis cases
2,165
West Nile cases
21
Zika cases
102

North Carolina's top USG-funded global health R&D institutions

Duke University
$250.1 million
FHI 360 (previously Family Health International)
$91.0 million
University of North Carolina
$46.4 million
University of North Carolina Chapel Hill/Carolina Vaccine Institute
$13.4 million
RTI International
$5.0 million
North Carolina State University Raleigh
$2.9 million
Wake Forest University
$553 thousand
Appalachian State University
$418 thousand
North Carolina Central University
$216 thousand

North Carolina industry in global health R&D

Alderon Biosciences
Location(s):
Beaufort
Argos Therapeutics
Location(s):
Durham
Avioq
Location(s):
Research Triangle Park
BASF Corporation
Location(s):
Research Triangle Park
Bavarian Nordic
Location(s):
Morrisville
Bayer
Location(s):
Clayton, Morrisville, Research Triangle Park
BD
Location(s):
Research Triangle Park
Biocryst Pharmaceuticals
Location(s):
Durham
Celgene
Location(s):
Durham
Charles River Laboratories
Location(s):
Durham, Morrisville, Raleigh
Collaborations Pharmaceuticals
Location(s):
Raleigh
Eisai
Location(s):
Raleigh
Envigen
Location(s):
Research Triangle Park
GSK
Location(s):
Research Triangle Park, Zebulon
Indexus Biomedical
Location(s):
Durham
Merck & Co
Location(s):
Durham, Wilson
Mucommune
Location(s):
Chapel Hill
Mycosynthetix
Location(s):
Hillsborough
NETE Solutions
Location(s):
Morrisville
Novartis
Location(s):
Holly Springs, Wilson
Pathfinder Pharma
Location(s):
Durham
Ribometrix
Location(s):
Durham, Chapel Hill
Sygenta
Location(s):
Greensboro
Viamet Pharmaceuticals
Location(s):
Durham
ViiV Healthcare
Location(s):
Research Triangle Park
Westat
Location(s):
Durham

North Carolina's top areas of global health R&D by USG funding

84.0%
HIV/AIDS
4.6%
Malaria
4.4%
Tuberculosis
2.8%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Trachoma
4.3%
Other
Bacteria pneumonia & meningitis
Cryptococcal meningitis
Diarrheal diseases
Ebola/viral hemorrhagic fevers
Hepatitis C
Non-allocable
Salmonella infections

Global health R&D at work in North Carolina

RTI International, in partnership with TB Alliance, is supporting development of new drugs for tuberculosis. One new drug therapy, PaMZ, promises to dramatically shorten and simplify treatment for multidrug-resistant tuberculosis (MDR-TB). Today people with MDR-TB face up to two years of treatment with only a 50 percent success rate. This game-changing therapy now in late-stage development is expected to decrease treatment to 6 months and reduce costs by 90 percent.

Footnotes